Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer

被引：0
|
作者：
Elshenawy, M. [1 ]
Badran, A. [2 ]
Al Jubran, A. [3 ]
Alzahrani, A. [3 ]
Rauf, M. [3 ]
Eldali, A. [3 ]
Bazarbashi, S. [3 ]
机构：
[1] Menoufia Univ, Fac Med, Shibin Al Kawm, Egypt
[2] Ain Shams Univ, Fac Med, Cairo, Egypt
[3] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-30
引用
收藏
页码：S99 / S99
页数：1
相关论文
共 50 条
  • [1] Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
    Elshenawy, Mahmoud A.
    Badran, Ahmed
    Aljubran, Ali
    Alzahrani, Ahmed
    Rauf, M. Shahzad
    Eldali, Abdelmoneim
    Bazarbashi, Shouki
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [2] Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
    Mahmoud A. Elshenawy
    Ahmed Badran
    Ali Aljubran
    Ahmed Alzahrani
    M. Shahzad Rauf
    Abdelmoneim Eldali
    Shouki Bazarbashi
    World Journal of Surgical Oncology, 18
  • [3] First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Cupini, Samanta
    Baldi, Giacomo Giulio
    Fornaro, Lorenzo
    Stasi, Irene
    Salvatore, Lisa
    Falcone, Alfredo
    PLATINUM AND OTHER HEAVY METAL COMPOUNDS IN CANCER CHEMOTHERAPY: MOLECULAR MECHANISMS AND CLINICAL APPLICATIONS, 2009, : 285 - 293
  • [4] Efficacy of second-line chemotherapy after a first-line triplet in patients with metastatic colorectal cancer
    Bazarbashi, S.
    Hakoun, A. M.
    Gad, A. M.
    Elshenawy, M. A.
    Aljubran, A.
    Alzahrani, A. M.
    Eldali, A.
    CURRENT ONCOLOGY, 2019, 26 (01) : E24 - E29
  • [5] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [6] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
  • [7] Hypertension and survival in unresectable metastatic colorectal cancer (mCRC) patients receiving first-line bevacizumab (BEV) and FOLFOX.
    Burnette, B. L.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [9] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
  • [10] Survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.
    Tsai, Hsiang-Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 56 - 56
12345